We have performed simultaneous X‐ray and radio observations of 13 Galactic Centre low‐mass X‐ray binaries in 1998 April using the Wide Field Cameras on board BeppoSAX and the Australia Telescope Compact Array, the latter simultaneously at 4.8 and 8.64 GHz. We detect two Z sources, GX 17+2 and GX 5−1, and the unusual ‘hybrid’ source GX 13+1. Upper limits, which are significantly deeper than previous non‐detections, are placed on the radio emission from two more Z sources and seven atoll sources. Hardness–intensity diagrams constructed from the Wide Field Camera data reveal GX 17+2 and GX 5−1 to have been on the lower part of the horizontal branch and/or the upper part of the normal branch at the time of the observations, and the two non‐detected Z sources, GX 340+0 and GX 349+2, to have been on the lower part of the normal branch. This is consistent with the previous empirically determined relation between radio and X‐ray emission from Z sources, in which radio emission is strongest on the horizontal branch and weakest on the flaring branch. For the first time we have information on the X‐ray state of atoll sources, which are clearly radio‐quiet relative to the Z sources, during periods of observed radio upper limits. We place limits on the linear polarization from the three detected sources, and use accurate radio astrometry of GX 17+2 to confirm that it is probably not associated with the optical star NP Ser. Additionally we place strong upper limits on the radio emission from the X‐ray binary 2S 0921−630, disagreeing with suggestions that it is a Z‐source viewed edge‐on.

Diagnostic categories do not completely reflect the heterogeneous expression of psychosis. Using data from the EU-GEI study, we evaluated the impact of schizophrenia polygenic risk score (SZ-PRS) and patterns of cannabis use on the transdiagnostic expression of psychosis. We analysed first-episode psychosis patients (FEP) and controls, generating transdiagnostic dimensions of psychotic symptoms and experiences using item response bi-factor modelling. Linear regression was used to test the associations between these dimensions and SZ-PRS, as well as the combined effect of SZ-PRS and cannabis use on the dimensions of positive psychotic symptoms and experiences. We found associations between SZ-PRS and (1) both negative (B = 0.18; 95%CI 0.03–0.33) and positive (B = 0.19; 95%CI 0.03–0.35) symptom dimensions in 617 FEP patients, regardless of their categorical diagnosis; and (2) all the psychotic experience dimensions in 979 controls. We did not observe associations between SZ-PRS and the general and affective dimensions in FEP. Daily and current cannabis use were associated with the positive dimensions in FEP (B = 0.31; 95%CI 0.11–0.52) and in controls (B = 0.26; 95%CI 0.06–0.46), over and above SZ-PRS. We provide evidence that genetic liability to schizophrenia and cannabis use map onto transdiagnostic symptom dimensions, supporting the validity and utility of the dimensional representation of psychosis. In our sample, genetic liability to schizophrenia correlated with more severe psychosis presentation, and cannabis use conferred risk to positive symptomatology beyond the genetic risk. Our findings support the hypothesis that psychotic experiences in the general population have similar genetic substrates as clinical disorders.

No abstract

Aim: Clinical staging of schizophrenia entails a new method that identifies clusters of symptoms and variation in level of remission, with the goal to create a framework for early intervention. Additionally, duration of untreated psychosis (DUP) may influence symptom severity in the first episode of psychosis (FEP) and could necessitate refining of the staging model. However, consistent evidence concerning variation in symptom severity and DUP between stages is missing. Therefore, we evaluated the clinical validity of the staging model by investigating differences in symptom severity across stages in schizophrenia spectrum disorders. Second, we assessed if a prolonged DUP is associated with higher symptom severity in FEP. Methods: We performed a cross-sectional study of 291 acutely admitted patients with a schizophrenia spectrum disorder. Patients were assigned to clinical stages following the definition of McGorry. Symptom severity was evaluated with the new DSM-5 Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS). In FEP, we determined the DUP. Results: Significantly higher severity scores of CRDPSS items hallucinations

this study demonstrates that clinical staging in schizophrenia spectrum disorders has an acceptable construct validity between earlier and more chronic stages of disease. Several clinical profilers increase in more advanced stages compared to earlier clinical stages, which supports construct validity.

No abstract

No abstract

No abstract